Acousia Therapeutics

Acousia Therapeutics is a clinical-stage biotechnology company led by CEO Tim Boelke, dedicated to identifying small molecules for the effective prevention and treatment of various causes of hearing loss. Acousia focuses on developing proprietary drug candidates designed to target sensory outer hair cells (OHC) in the cochlea of the inner ear. Its small molecule Kv7.4 activators feature a unique dual mode of action combining acute functional OHC enhancement with sustained OHC protection, aiming to enhance and preserve patients' natural hearing. Acousia Therapeutics develops drugs for both local and systemic administration.